ArticleScientific reports2026
Upregulation of serum circular RNA FUNDC1 and TNF-α in Behçet's disease: potential diagnostic biomarkers.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Behçet's disease (BD) is an inflammatory autoimmune disease characterized by relapsing genital ulcers, ocular involvement, and intestinal disorders. Evaluate serum levels of circular RNA (circRNA) FUNDC1 and tumor necrosis factor-alpha (TNF-α) in BD patients and compare them accordingly to healthy individuals. One hundred participants were enrolled in this study and subdivided equally into BD patients and healthy matched individuals. A five mL sample of blood was drawn from each subject and analyzed to measure circRNA-FUNDC1 and TNF-α. Full clinical investigations have been performed, and the Behcet Disease Current-Activity Form score (BDCAF) has been calculated. circRNA-FUNDC1 and TNF-α were measured by quantitative real time PCR and enzyme-linked immunosorbent assay (ELISA) respectively. An up-regulation of circRNA-FUNDC1 as well as TNF-α (p < 0.0001) in BD group were reported compared to controls. Both biomarkers tended to elevate with the activity of the disease as levels were higher in active BD patients than inactive patients. The level of circRNA-FUNDC1 (FC) tended to be higher in patients with negative musculoskeletal and central nervous system (CNS) manifestations than those with positive manifestations (p-values = 0.007, 0.037, respectively). The level of TNF-α was reported higher in those with oral ulcer with (p = 0.041), also in patients with positive skin manifestations than in negative patients (p = 0.025). The level of circRNA-FUNDC1 (FC) was higher in patients who took Azathioprine and steroids (p = 0.019, 0.035) and lower in patients who took cyclosporin (p = 0.049). TNF-α tended to elevate in patients who took Hydroxychloroquine than those who did not (p = 0.040). The upregulated levels of circRNA-FUNDC1 and TNF-α may have a potential role in improving our understanding of the molecular mechanisms underlying BD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.